Clinical evaluation of clobetasone butyrate eye drops in episcleritis.
Thirty-nine patients took part in a double-blind, between-patient clinical trial to compare clobetasone butyrate, betamethasone phosphate, and placebo eye drops in the treatment of episcleritis. Although from the symptom scores the patients given placebo appeared to do as well as the other patients in the first week of treatment, they did significantly less well after this time. Clobetasone butyrate and betamethasone phosphate eye drops seemed to be equally effective in the treatment of this disease.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D007429:Intraocular Pressure / Q000187:drug effects; D012590:Sclera
D000893:Anti-Inflammatory Agents; C028994:betamethasone sodium phosphate; C010893:clobetasone butyrate; D001623:Betamethasone; D002990:Clobetasol